Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$131.82

0.29 (0.22%)

, BAYRY

Bayer

$133.06

0.01 (0.01%)

06:04
06/13/17
06/13
06:04
06/13/17
06:04

Bayer, J&J cleared of liability in second Xarelto trial, Reuters reports

Bayer (BAYRY) and Johnson & Johnson (JNJ) have been cleared of liability by a federal jury in the second trial stemming from thousands of lawsuits blaming injuries on Xarelto, a blood thinning drug, Reuters reports. Reference Link

JNJ

Johnson & Johnson

$131.82

0.29 (0.22%)

BAYRY

Bayer

$133.06

0.01 (0.01%)

  • 13

    Jun

  • 15

    Jun

  • 26

    Jun

JNJ Johnson & Johnson
$131.82

0.29 (0.22%)

06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/07/17
FBCO
06/07/17
NO CHANGE
Target $38
FBCO
Outperform
ASCO meeting highlights pressure on Pfizer cancer assets, says Credit Suisse
Credit Suisse analyst Vamil Divan said he came away from the ASCO meeting feeling like positive progress by competitors is increasing the pressure on Pfizer's (PFE) cancer assets, specifically pointing to positive data for Roche's (RHHBY) Alecensa, Johnson & Johnson's (JNJ) Zytiga and Eli Lilly's (LLY) abemaciclib. Additionally, competition in the immune-oncology and PARP spaces will make it more challenging for Pfizer to gain traction, added Divan. He keeps an Outperform rating on Pfizer, citing valuation and its dividend yield, but he has concerns about its upcoming patent expirations and growth products.
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Tesaro prostate study suspension due to fast enrollment, says Credit Suisse
After speaking to Tesaro (TSRO), after they spoke to their partner Johnson & Johnson (JNJ), Credit Suisse analyst Alethia Young said the news of the companies' suspension of participant recruitment in the study of niraparib in prostate cancer is actually positive, since it is due to the trial enrolling faster than expected. The suspension has nothing to do with safety or efficacy and is not a clinical hold, but is due to having too many patients in the first part of trial, Young was told. She maintains an Outperform rating on Tesaro shares.
06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
Misunderstanding creates buying opportunity in Tesaro stock, says SunTrust
SunTrust analyst Peter Lawson says that the suspension of participant recruitment by Johnson & Johnson (JNJ) for a study of Tesaro's (TSRO) PARP inhibitor Zejula in prostate cancer "is being incorrectly viewed as a clinical hold." After speaking with J&J, Lawson says that the suspension was not due to clinical or safety issues, but to overly fast enrollment. The analyst says that the early data on PARP inhibitors in prostate cancer has been "encouraging." He believes that the misunderstanding has created a buying opportunity in Tesaro stock. .
BAYRY Bayer
$133.06

0.01 (0.01%)

01/06/17
JPMS
01/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares are mispriced, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says Monsanto (MON) shares are mispriced and offer an attractive risk/reward proposition. A first catalyst for the shares would be regulatory agreement in the Dow Chemical (DOW)/DuPont (DD) transaction, Zekauskas tells investors in a research note. The analyst thinks a favorable resolution to the Dow/DuPont merger would be seen as improving the probability of the success of the Bayer/Monsanto transaction. He notes that Bayer has agreed to purchase Monsanto for $128 per share in cash, which represents 21% appreciation potential should the deal close by year-end. Zekauskas thinks a "reasonable floor" price for Monsanto shares, should the deal fail, is $102. He keeps an Overweight rating on the name with a $128 price target.
03/03/17
JPMS
03/03/17
NO CHANGE
Target $128
JPMS
Overweight
EU approvals of other ag deals may narrow Monsanto deal spread, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas said commentary from the CEOs of DuPont (DD) and Syngenta (SYT) and press reports from Europe suggest that their deals with Dow Chemical (DOW) and ChemChina, respectively, are likely to be approved. Approvals from Europe for those deals may "trigger a meaningful closing of the arbitrage spread" in Monsanto (MON) shares versus Bayer's (BAYRY) offer price, Zekauskas tells investors. He recommends buying Monsanto shares at current levels for this reason, adding that he believes the shares would only fall about 2.5%, or down to $112, in the event of the Bayer deal falling through. Zekauskas keeps an Overweight rating and $128 price target on Monsanto shares, which closed yesterday at just below $115 per share.
04/06/17
JPMS
04/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares offer 'excellent' risk/reward proposition, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says shares of Monsanto (MON) at current levels offer an "excellent" risk/reward proposition. The analyst views capital appreciation potential to the end of 2017 as 11% or a 15% annual return. He sees downside risk of only 3%, to $112 per share, in the event that Bayer (BAYRY) is not able to consummate the acquisition. Zekauskas has increased confidence in the deal closing following recent regulatory rulings and keeps an Overweight rating on the name with a $128 price target.
04/10/17
PIPR
04/10/17
NO CHANGE
Target $17
PIPR
Overweight
OncoMed price target lowered to $17 from $26 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for OncoMed (OMED) to $17 from $26 following two negative announcements, namely that the Phase II YOSEMITE study of demcizumab in first line pancreatic cancer failed and Bayer (BAYRY) returned rights for ipafricept and vantictumab. The analyst also notes that now partner Celgene (CELG) will review all data on demcizumab including Phase II DENALI non-small cell lung cancer data and Phase Ib combo data with KEYTRUDA, although he does not expect Celgene to exercise its option. Tenthoff reiterates an Overweight rating on OncoMed's shares.

TODAY'S FREE FLY STORIES

ATU

Actuant

$22.90

-0.2 (-0.87%)

19:22
08/16/17
08/16
19:22
08/16/17
19:22
Hot Stocks
Actuant agrees to divest Viking SeaTech, acquire Mirage Machines »

Actuant Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVO

Novo Nordisk

$46.41

0.9 (1.98%)

19:17
08/16/17
08/16
19:17
08/16/17
19:17
Hot Stocks
Novo Nordisk: SUSTAIN 7 results show superior reduction in HbA1c »

Novo Nordisk announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

GOOG

Alphabet

$926.96

4.74 (0.51%)

, GOOGL

Alphabet Class A

$944.27

6.19 (0.66%)

18:48
08/16/17
08/16
18:48
08/16/17
18:48
Periodicals
Google acquires AIMatter, TechCrunch reports »

Google has acquired…

GOOG

Alphabet

$926.96

4.74 (0.51%)

GOOGL

Alphabet Class A

$944.27

6.19 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 18

    Aug

  • 24

    Aug

SRUN

Silver Run

$10.19

0.01 (0.10%)

18:37
08/16/17
08/16
18:37
08/16/17
18:37
Hot Stocks
Silver Run merging with Alta Mesa and Kingfisher Midstream into $3.8B company »

Silver Run Acquisition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEI

Heico

$85.55

-0.87 (-1.01%)

18:37
08/16/17
08/16
18:37
08/16/17
18:37
Downgrade
Heico rating change  »

Heico downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 07

    Sep

GPRK

GeoPark

$8.61

-0.13 (-1.49%)

18:36
08/16/17
08/16
18:36
08/16/17
18:36
Earnings
GeoPark reports Q2 revenue $75.2M, consensus $70.38M »

Reports Q2 consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

MEDP

Medpace

$31.21

-0.16 (-0.51%)

18:14
08/16/17
08/16
18:14
08/16/17
18:14
Hot Stocks
Medpace announces stock repurchase agreement with Cinven »

Medpace Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

TOUR

Tuniu

$7.76

-0.18 (-2.27%)

18:04
08/16/17
08/16
18:04
08/16/17
18:04
Earnings
Tuniu reports Q2 EPS (11c), consensus (26c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

GLDD

Great Lakes Dredge

$3.85

-0.15 (-3.75%)

18:03
08/16/17
08/16
18:03
08/16/17
18:03
Hot Stocks
Great Lakes Dredge CEO acquires 42,610 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TISI

Team

$11.10

-0.25 (-2.20%)

18:00
08/16/17
08/16
18:00
08/16/17
18:00
Hot Stocks
Team director Lois Waters purchases 17,500 shares of company stock »

Team director Lois Waters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$42.41

0.44 (1.05%)

17:59
08/16/17
08/16
17:59
08/16/17
17:59
Hot Stocks
Breaking Hot Stocks news story on NetApp »

NetApp says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

  • 14

    Sep

NTAP

NetApp

$42.41

0.44 (1.05%)

17:58
08/16/17
08/16
17:58
08/16/17
17:58
Hot Stocks
Breaking Hot Stocks news story on NetApp »

NetApp says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

  • 14

    Sep

NTAP

NetApp

$42.42

0.44 (1.05%)

17:52
08/16/17
08/16
17:52
08/16/17
17:52
Earnings
NetApp sees low double digit EPS growth for FY18, consensus $3.03 »

Sees FY18 adjusted gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

  • 14

    Sep

SFST

Southern First Bancshares

$36.00

0.05 (0.14%)

17:50
08/16/17
08/16
17:50
08/16/17
17:50
Hot Stocks
Southern First Bancshares CFO Michael Dowling sells 5,850 shares »

Southern First Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

BXE

Bellatrix Exploration

$2.40

-0.03 (-1.23%)

17:49
08/16/17
08/16
17:49
08/16/17
17:49
Hot Stocks
Bellatrix Exploration regains NYSE minimum price compliance »

Bellatrix Exploration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$42.41

0.44 (1.05%)

17:48
08/16/17
08/16
17:48
08/16/17
17:48
Hot Stocks
NetApp says headwind for services revenue to decrease in coming quarters »

Comments from Q1 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

  • 14

    Sep

ACHN

Achillion

$4.88

-0.12 (-2.40%)

17:45
08/16/17
08/16
17:45
08/16/17
17:45
Conference/Events
Achillion management to meet with William Blair »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

BCOR

Blucora

$23.35

0.1 (0.43%)

, BBOX

Black Box

$3.75

-0.25 (-6.25%)

17:35
08/16/17
08/16
17:35
08/16/17
17:35
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Blucora (BCOR),…

BCOR

Blucora

$23.35

0.1 (0.43%)

BBOX

Black Box

$3.75

-0.25 (-6.25%)

BGG

Briggs & Stratton

$24.09

0.29 (1.22%)

LB

L Brands

$39.55

0.5 (1.28%)

VIPS

Vipshop

$11.10

-0.07 (-0.63%)

SPTN

SpartanNash

$25.96

0.07 (0.27%)

SNPS

Synopsys

$79.09

0.86 (1.10%)

CSCO

Cisco

$32.34

0.25 (0.78%)

NTAP

NetApp

$42.41

0.44 (1.05%)

LAKE

Lakeland Industries

$15.65

-0.25 (-1.57%)

GCP

GCP Applied Technologies

$28.75

0.1 (0.35%)

FNGN

Financial Engines

$34.35

-0.1 (-0.29%)

ACHC

Acadia

$51.68

-0.33 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

  • 16

    Aug

  • 17

    Aug

  • 17

    Aug

  • 17

    Aug

  • 29

    Aug

  • 06

    Sep

  • 06

    Sep

  • 06

    Sep

  • 14

    Sep

  • 30

    Nov

  • 17

    Aug

  • 17

    Aug

  • 17

    Aug

ANDX

Andeavor Logistics

$46.94

0.12 (0.26%)

, WNRL

Western Refining Logistics

$24.25

0.1 (0.41%)

17:26
08/16/17
08/16
17:26
08/16/17
17:26
Upgrade
Andeavor Logistics, Western Refining Logistics rating change at MUFG »

Andeavor Logistics…

ANDX

Andeavor Logistics

$46.94

0.12 (0.26%)

WNRL

Western Refining Logistics

$24.25

0.1 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$200.61

1.12 (0.56%)

17:22
08/16/17
08/16
17:22
08/16/17
17:22
Hot Stocks
General Dynamics awarded $115.3M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

BLVD

Boulevard Acquisition

$10.04

-0.01 (-0.10%)

17:17
08/16/17
08/16
17:17
08/16/17
17:17
Hot Stocks
Breaking Hot Stocks news story on Boulevard Acquisition »

Glazer Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMBH

First Mid-Illinois Bancshares

$34.85

-0.33 (-0.94%)

17:17
08/16/17
08/16
17:17
08/16/17
17:17
Syndicate
First Mid-Illinois Bancshares files to sell $20M of common stock 'at-the-market' »

First Mid-Illinois…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

NCOM

National Commerce

$39.55

0.1 (0.25%)

17:16
08/16/17
08/16
17:16
08/16/17
17:16
Hot Stocks
National Commerce, FirstAtlantic Financial sign definitive merger agreement »

National Commerce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

AMGN

Amgen

$171.39

1.35 (0.79%)

17:13
08/16/17
08/16
17:13
08/16/17
17:13
Hot Stocks
Amgen: NEJM publishes results from Repatha cognitive function trial »

Amgen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 18

    Aug

  • 08

    Sep

  • 14

    Sep

  • 02

    Dec

  • 03

    Feb

  • 17

    May

WLK

Westlake Chemical

$71.03

0.84 (1.20%)

17:13
08/16/17
08/16
17:13
08/16/17
17:13
Hot Stocks
Westlake Chemical CFO Mark Bender sells 13,794 shares of company stock »

Mark Bender, Westlake…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.